重大事件即時報告 8-K 2026-07-21

Tonix製藥提交8-K 披露首席醫療官Sullivan博士將於8月退休

AI 繁中摘要

Tonix Pharmaceuticals Holding Corp.（納斯達克代碼：TNXP）於2026年7月20日提交8-K申報，披露首席醫療官 Gregory M. Sullivan 博士將於2026年8月20日正式退休。Sullivan 博士已通知公司其離任決定，並將在過渡期內協助交接。

此項人事變動屬高層管理人員離職，暫未提及繼任人選或具體過渡安排。投資者需關注公司後續是否公布新任首席醫療官，以及臨床開發項目是否會受影響。Tonix 目前正專注於中樞神經系統及罕見疾病藥物研發，管理層穩定對臨床進度及監管溝通至關重要。公司將於未來數月更新相關進展。

展開英文正文

false
 0001430306
 
 
 
 
 
 
 
 0001430306
 
 
 2026-07-20
 2026-07-20
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES 

SECURITIES
AND EXCHANGE COMMISSION 

Washington,
D.C. 20549

 

FORM
8-K

 

CURRENT
REPORT

 

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date
of report (date of earliest event reported): July 20, 2026

 

TONIX
PHARMACEUTICALS HOLDING CORP.

(Exact
name of registrant as specified in its charter)

 

 
 Nevada
  
 001-36019
  
 26-1434750

 
 (State
 or Other Jurisdiction 

 of
 Incorporation) 

  
 (Commission
 

 File
 Number)

  
 (IRS
 Employer 

 Identification
 No.)

 
 

200
Connell Drive, Suite 3100, Berkeley Heights, New Jersey 07922

(Address
of principal executive offices) (Zip Code)

 

Registrant’s
telephone number, including area code: (862) 799-8599

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

 

 
 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 
  
  

 
 ☐
  Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 
  
  

 
 ☐
  Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Common
 Stock
  
 TNXP
  
 The
 NASDAQ Global
 Select Market

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging
growth company ☐

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. 

 

On
July 20, 2026, Dr. Gregory M. Sullivan informed Tonix Pharmaceuticals Holding Corp. (the “Company”) that he will retire from
his role as Chief Medical Officer of the Company, effective August 20, 2026.

 

  

  

 

 

SIGNATURE

 

Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

 

 
  
 TONIX
 PHARMACEUTICALS HOLDING CORP.

 
  
  

 
 Date:
 July 21, 2026
 By:
 
 /s/
 Bradley Saenger
 

 
  
  
 Bradley
 Saenger
 

 
  
  
 Chief
 Financial Officer